Kobatake Eiji, Iwama Yoshitaka, Arai Toshinobu, Shioya Nobuhiko, Kise Mai, Kabuki Toshihide
Milk Science Research Institute, MEGMILK SNOW BRAND Co., Ltd., Saitama, Japan.
Nihonbashi Cardiology Clinic, Tokyo, Japan.
Front Nutr. 2022 Dec 8;9:1063584. doi: 10.3389/fnut.2022.1063584. eCollection 2022.
SBT2055 (LG2055) has been reported to show immunostimulating effects. This study aimed to investigate the effects of LG2055 on the subjective symptoms of the physical condition in healthy adults.
In this randomized, double-blind, placebo-controlled, parallel-group comparative study, Japanese individuals aged 20-64 years were recruited. A total of 200 participants were randomly divided into two groups by an independent controller (LG2055 and placebo groups; 100 participants per group). Drinkable yogurts containing LG2055 or lacking LG2055 (placebo) were used as test samples. The participants ingested one bottle of the test sample once a day for 12 weeks. A daily physical health questionnaire survey (about common cold symptoms) was performed as the primary outcome, and immunological and oxidative stress markers in saliva and serum were evaluated as secondary outcomes.
In total, 198 participants completed the scheduled intake of the test samples, and five participants were excluded from the final analysis. Consequently, 193 participants (LG2055 group, = 97; placebo group, = 96) in the Per-Protocol Set were included in the efficacy analysis. The cumulative days of each symptom were evaluated, and the LG2055 group showed a significantly higher ratio of "without symptom" in runny nose, plugged nose, sneezing, sore throat, hoarseness, cough, headache, feeling tired, and fever than the placebo group, indicating that the incidence rates of common cold symptoms were lower in the LG2055 group. Additionally, changes in the salivary secretory IgA levels were significantly higher, and the serum derivatives of reactive oxygen metabolites levels were significantly lower in the LG2055 group.
Our study revealed that intake of LG2055 decreased common cold symptoms and improved immune parameters in healthy adults. This suggests that LG2055 contributes to the maintenance of physical conditions by improving the host immune system.
[https://www.umin.ac.jp/ctr/index.htm], identifier [UMIN000045901].
据报道，SBT2055（LG2055）具有免疫刺激作用。本研究旨在调查LG2055对健康成年人身体状况主观症状的影响。
在这项随机、双盲、安慰剂对照、平行组比较研究中，招募了20至64岁的日本个体。总共200名参与者由独立的控制器随机分为两组（LG2055组和安慰剂组；每组100名参与者）。含有LG2055或不含LG2055（安慰剂）的可饮用酸奶用作测试样品。参与者每天饮用一瓶测试样品，持续12周。进行每日身体健康问卷调查（关于普通感冒症状）作为主要结果，并评估唾液和血清中的免疫和氧化应激标志物作为次要结果。
共有198名参与者完成了测试样品的预定摄入，5名参与者被排除在最终分析之外。因此，符合方案集的193名参与者（LG2055组，n = 97；安慰剂组，n = 96）被纳入疗效分析。评估了每种症状的累计天数，LG2055组在流鼻涕、鼻塞、打喷嚏、喉咙痛、声音嘶哑、咳嗽、头痛、感到疲倦和发烧方面“无症状”的比例显著高于安慰剂组，表明LG2055组普通感冒症状的发生率较低。此外，LG2055组唾液分泌型IgA水平的变化显著更高，血清活性氧代谢产物衍生物水平显著更低。
我们的研究表明，摄入LG2055可减轻健康成年人的普通感冒症状并改善免疫参数。这表明LG2055通过改善宿主免疫系统有助于维持身体状况。
